BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36808598)

  • 1. Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in China.
    Lin Z; Zha J; Yi S; Li Z; Ping L; He X; Fan L; Yu H; Zheng Z; Xu W; Chen F; Xie Y; Chen B; Zhang H; Wang L; Ding K; Li W; Yang H; Zhao W; Qiu L; Li Z; Song Y; Xu B
    Clin Transl Oncol; 2023 Jun; 25(6):1821-1829. PubMed ID: 36808598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical Features, Treatment and Prognostic Factors of 94 Patients with Follicular Lymphoma].
    DU XY; Hu K; Zhao W; Yang P; Wan W; Jing HM; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):756-764. PubMed ID: 29950216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
    Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
    Takahashi H; Tomita N; Yokoyama M; Tsunoda S; Yano T; Murayama K; Hashimoto C; Tamura K; Sato K; Ishigatsubo Y
    Cancer; 2012 Sep; 118(17):4166-72. PubMed ID: 22213346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
    Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
    Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era.
    Chen Y; Luo L; Chen L; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Yang T; Hu J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2311-2318. PubMed ID: 36219261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical Features of Diffuse Large B-Cell Lymphoma Transformed from Follicular Lymphoma].
    Zhang XL; Yu WJ; Zhu YN; Yang CM; Xiao F; Mai WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1772-1778. PubMed ID: 36476902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
    Bobillo S; Joffe E; Lavery JA; Sermer D; Ghione P; Noy A; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Moskowitz A; Owens CN; Palomba ML; Batlevi CL; Straus D; von Keudell G; Zelenetz AD; Yahalom J; Dogan A; Seshan VE; Younes A
    Blood; 2021 Jan; 137(1):39-48. PubMed ID: 32730585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
    Castillo JJ; Winer ES; Olszewski AJ
    Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China.
    Zha J; Fan L; Yi S; Yu H; Zheng Z; Xu W; Deng M; Lin Z; Li Z; Ping L; He X; Chen F; Xie Y; Chen B; Zhang H; Wang L; Ding K; Li W; Yang H; Zhao W; Qiu L; Li Z; Song Y; Xu B
    J Hematol Oncol; 2021 Aug; 14(1):131. PubMed ID: 34425858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic study of 229 follicular lymphoma patients treated with rituximab combined with chemotherapy].
    Wang N; Xu PP; Wang L; Cheng S; Zhao WL; Sun HP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):46-51. PubMed ID: 30704228
    [No Abstract]   [Full Text] [Related]  

  • 15. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era.
    Lu CS; Chen JH; Huang TC; Wu YY; Chang PY; Dai MS; Chen YC; Ho CL
    Leuk Lymphoma; 2015 Jul; 56(7):2047-55. PubMed ID: 25382616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.
    Jin J; Gui A; Chen G; Liu Y; Xia Z; Liu X; Lv F; Cao J; Hong X; Yang L; Gu JJ; Zhang Q
    Int J Hematol; 2022 Sep; 116(3):372-380. PubMed ID: 35536508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma.
    Fernández de Larrea C; Martínez-Pozo A; Mercadal S; García A; Gutierrez-García G; Valera A; Ghita G; Colomo L; Gainza E; Villamor N; Nomdedeu B; Estrach T; Montserrat E; Campo E; López-Guillermo A
    Br J Haematol; 2011 May; 153(3):334-40. PubMed ID: 21375524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.